Evaluation and treatment of resistant or difficult-to-control hypertension

Journal of Clinical Hypertension

Volumn 10, Issue 11, 2008, Pages 837-843

  Wojciechowski, David ^a   Papademetriou, Vasilios ^a   Faselis, Charles ^a   Fletcher, Ross ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; MINOXIDIL; SPIRONOLACTONE; ANTIHYPERTENSIVE AGENT;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; DIASTOLE; DRUG EFFECT; DRUG RESISTANCE; ETHNOLOGY; LIFESTYLE; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; STATISTICS; SYSTOLE; UNITED STATES;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMORBIDITY; DIASTOLE; DISTRICT OF COLUMBIA; DRUG RESISTANCE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; LIFE STYLE; MALE; MIDDLE AGED; PREVALENCE; SYSTOLE; UNITED STATES;

EID: 60749118941     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.00037.x     Document Type: Article

References (26)

1. The Seventh Report of the Joint National Committee on the detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA. 2003; 289: 2560-2572.
2. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac organ damage in refractory hypertension. J Hypertens. 2001; 19: 2063-2070.
3. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001; 345: 479-486.
4. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension. 2004; 44: 398-404.
5. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 summary. Adv Data. 2002; 4: 1-32.
6. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290: 199-206.
7. Moser M, Franklin SS. Hypertensive management: Results of a new national survey for the Hypertension Education Foundation: Harris interactive. J Clin Hypertens (Greenwich). 2007; 9 (5): 316-323.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
9. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension. 2002; 40: 464-469.
10. Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005; 18: 619-626.
11. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: Comparing hemodynamic management to specialist care. Hypertension. 2002; 39: 982-988.
12. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new predictive equation. Ann Intern Med. 1999; 130: 461-470.
13. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. http://www.hyper.ahajournals.org. Accessed April 7, 2008.
14. Werlemann BC, Offers E, Kolloch R. Compliance problems in therapy resistant hypertension. Herz. 2004; 29: 271-275.
15. Taler SJ. Treatment of resistant hypertension. Curr Hypertens Rep. 2005; 7: 323-329.
16. Brown MJ, Castaigne A, de Leeuw PW, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension. 2000; 35: 1038-1042.
17. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003; 289: 2073-2082.
18. Moser M, Setaro J. Resistant or difficult to control hypertension. N Engl J Med. 2006; 355: 385-392.
19. Graves JW, Bloomfild RL, Buckalew VM. Plasma volume in resistant hypertension: Guide to pathophysiology and therapy. Am J Med Sci. 1989; 298: 361-365.
20. Papadopoulos DP, Papademetriou V. Resistant hypertension: Diagnosis and management. J Cardiovasc Pharmacol Ther. 2006; 11: 113-118.
21. Materson BJ. Lessons on the interaction of race and antihypertensive drugs from the VA cooperative study group on antihypertensive agents. Am J Hypertens. 1995; 8: 91s-93s.
22. Andersson O. Management of hypertension. Clinical and hemodynamic studies with special reference to patients refractory to treatment. Acta Med Scand Suppl. 1977; 617: 1-62.
23. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002; 4: 221-228.
24. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med. 2003; 139: 244-252.
25. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002; 288: 2421-2431.
26. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: Why is it so resistant to treatment? Kidney Int. 2006; 69: 967-973.